Synthesis and SAR of potent EGFR/erbB2 dual inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 111-114

  Zhang, Yue Mei ^a,b   Cockerill, Stuart ^a,c   Guntrip, Stephen B ^a   Rusnak, David ^a   Smith, Kathryn ^a   Vanderwall, Dana ^a   Wood, Edgar ^a   Lackey, Karen ^a  

^a GLAXOSMITHKLINE   (United States)

^b J and J Pharmaceutical Research and Development   (United States)

^c Arrow Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 ALKOXY 4 ANILINOQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

EID: 0347517814     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.010     Document Type: Article

References (19)

1. Aaronson S.A. Science. 254:1991;1146 Hung M., Lau Y. Semin. Oncol. 26:1999;51.
2. Aaronson S.A. Science. 254:1991;1146 Hung M., Lau Y. Semin. Oncol. 26:1999;51.
3. Kersemaekers A.M.F., Fleuren G.J., Kenter E.G., Van den Broek L.J.C.M., Uljee S.M., Hermans J., Van de Vijver M. J. Clin. Cancer Res. 5:1999;577.
4. Earp H.S., Dawson T.L., Li X., Yu H. Breast Cancer Res. Treat. 35:1995;115 GRAU-Porta D., Beerli R.R., Daly J.M., Hynes N.E. EMBO J. 16:1997;1647.
5. Earp H.S., Dawson T.L., Li X., Yu H. Breast Cancer Res. Treat. 35:1995;115 GRAU-Porta D., Beerli R.R., Daly J.M., Hynes N.E. EMBO J. 16:1997;1647.
6. For Herceptin: Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. J. Clin. Oncol. 14:1996;737. For C225: Waksal H.W. Cancer Metastasis Rev. 18:2000;427.
7. For Herceptin: Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. J. Clin. Oncol. 14:1996;737. For C225: Waksal H.W. Cancer Metastasis Rev. 18:2000;427.
8. Traxler P.M. Exp. Opin. Ther. Pat. 7:1997;571. . Traxler, P. M. Exp. Opin. Ther. Pat. 1998, 8, 1599.
9. Smaill J.B., Rewcastle G.W., Loo J.A., Greis K.D., Chan O.H., Reyner E.L., Lipka E., Showalter H.D.H., Vincent P.W., Elliott W.L., Denny W.A. J. Med. Chem. 43:2000;1380. , and references cited therein.
10. Smaill J.B., Palmer B.D., Rewcastle G.W., Denny W.A., McNamara D.J., Dobrusin E.M., Bridges A.J., Zhou H., Showalter H.D.H., Winters R.T., Leopold W.R., Fry D.W., Nelson J.M., Slintak V., Elliott W.L., Roberts B.J., Vincent P.W., Patmore S.J. J. Med. Chem. 42:1999;1803. , and references cited therein.
11. Traxeler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. J. Med. Chem. 40:1997;3601. , and references cited therein.
12. Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer Th., Muller M., Regenass U., Rihs G., Lydon N.B., Tralexer P. J. Med. Chem. 37:1994;1015.
13. Iwata K., Miller P.E., Barbacci E.G., Arnold L., Doty J., Diorio C.I., Pustilnik L.R., Reynolds M., Thelemann A., Sloan D., Moyer J.D. Proc. Am. Assoc. Cancer Res. 38:1997;633. (abstract 4248) Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. Proc. Am. Assoc. Cancer Res. 38:1997;633 Spector, N.; Raefsky, E.; Hurwitz, H.; Hensing, T.; Dowlati, A.; Dees, C.; O'Neil, B.; Koch, K.; Smith, D. A.; Mangum, S.; Burris, H. A. Safety, Clinical Efficacy, and Biologic Assessments from EGF10004: A Randomized Phase Ib Study of GW572016 for Patients with Metastatic Carcinomas Overexpressing EGFR or ErbB2. ASCO 2003. Proc. Am. Soc. Clin. Oncol. 22: page 193, 2003 (abstract 772).
14. Iwata K., Miller P.E., Barbacci E.G., Arnold L., Doty J., Diorio C.I., Pustilnik L.R., Reynolds M., Thelemann A., Sloan D., Moyer J.D. Proc. Am. Assoc. Cancer Res. 38:1997;633. (abstract 4248) Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. Proc. Am. Assoc. Cancer Res. 38:1997;633 Spector, N.; Raefsky, E.; Hurwitz, H.; Hensing, T.; Dowlati, A.; Dees, C.; O'Neil, B.; Koch, K.; Smith, D. A.; Mangum, S.; Burris, H. A. Safety, Clinical Efficacy, and Biologic Assessments from EGF10004: A Randomized Phase Ib Study of GW572016 for Patients with Metastatic Carcinomas Overexpressing EGFR or ErbB2. ASCO 2003. Proc. Am. Soc. Clin. Oncol. 22: page 193, 2003 (abstract 772).
15. Iwata K., Miller P.E., Barbacci E.G., Arnold L., Doty J., Diorio C.I., Pustilnik L.R., Reynolds M., Thelemann A., Sloan D., Moyer J.D. Proc. Am. Assoc. Cancer Res. 38:1997;633. (abstract 4248) Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. Proc. Am. Assoc. Cancer Res. 38:1997;633 Spector, N.; Raefsky, E.; Hurwitz, H.; Hensing, T.; Dowlati, A.; Dees, C.; O'Neil, B.; Koch, K.; Smith, D. A.; Mangum, S.; Burris, H. A. Safety, Clinical Efficacy, and Biologic Assessments from EGF10004: A Randomized Phase Ib Study of GW572016 for Patients with Metastatic Carcinomas Overexpressing EGFR or ErbB2. ASCO 2003. Proc. Am. Soc. Clin. Oncol. 22: page 193, 2003 (abstract 772).
16. Maillard J., Benard M., Vincent M., Vo-Van-Tri, Jolly R., Morin R., Benharkate M., Menillet C. Chim. Ther. 2:1967;231.
17. Carter, M. C.; Cockerill, G. S.; Guntrip, S. B.; Lackey, K. E.; Smith, K. J. WO 9935146 A1.
18. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., Wood E.R. J. Biol. Chem. 277:2002;1576.
19. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N.R., Keith B., Murray D.M., Mullin R.J., Knight W.B., Gilmer T.M. Mol. Cancer Ther. 1:2001;85.